Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.


TSXV:TELO - Post by User

Bullboard Posts
Comment by gooddogon Dec 19, 2016 10:50pm
94 Views
Post# 25622663

RE:RE:RE:PP

RE:RE:RE:PPI'm thinking Knight would be more than upset if that was the case.
At any rate, you will now tomorrow when you call

jammingthepipeline wrote: Who said that?   If it's true, then it's a bad move from the company against the " small fish" .  But I don't think it's true.  Let them buy on the open market.  Tomorrow I will call the office.


IMONTREAL, QUEBEC--(Marketwired - Dec. 19, 2016) - Knight Therapeutics Inc. ("Knight") (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that it invested $180,000 in 3D Signatures Inc. (TSX VENTURE:DXD) ("3DS") as part of a brokered private placement of approximately $3.9 million. As consideration, Knight received 240,000 common shares of 3DS and warrants to purchase an additional 240,000 shares of 3DS at an exercise price of $0.92 with an expiry date of December 16, 2018, subject to an acceleration clause.

Bullboard Posts